Success Metrics

Clinical Success Rate
11.1%

Based on 1 completed trials

Completion Rate
11%(1/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
8(89%)

Phase Distribution

Ph phase_3
9
100%

Phase Distribution

0

Early Stage

0

Mid Stage

9

Late Stage

Phase Distribution9 total trials
Phase 3Large-scale testing
9(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

11.1%

1 of 9 finished

Non-Completion Rate

88.9%

8 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(1)
Terminated(8)

Detailed Status

Terminated8
Completed1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
11.1%
Most Advanced
Phase 3

Trials by Phase

Phase 39 (100.0%)

Trials by Status

completed111%
terminated889%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

NCT00478972
terminatedphase_3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

NCT00478595
completedphase_3

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

NCT00299325
terminatedphase_3

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

NCT00263042
terminatedphase_3

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00478972Phase 3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

Terminated
NCT00478595Phase 3

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Terminated
NCT00299325Phase 3

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt

Completed
NCT00263042Phase 3

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

Terminated
NCT00228176Phase 3

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

Terminated
NCT00325650Phase 3

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

Terminated
NCT00576667Phase 3

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Terminated
NCT00577148Phase 3

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Terminated
NCT00690456Phase 3

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9